Evidence map›Paper›PMID 40080261›Full record

ReviewJournal of cardiovascular translational research2025

RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management.

Abbas Mohammadi, Azin Karimian, Kasra Shokri, Ashkan Mohammadi, Nazanin Hazhir-Karzar, Rayeheh Bahar, Azar Radfar, Mohammadreza Pakyari, Behnam Tehrani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abbas MohammadiDepartment of Internal Medicine, Valley Health System, Las Vegas, NV, USA. abbas_pr2005@hotmail.com.ORCID 0000-0001-9654-769X
Azin KarimianCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Kasra ShokriCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Ashkan MohammadiUniversity of Naples Federico II, Naples, Italy.
Nazanin Hazhir-KarzarDepartment of Internal Medicine, Valley Health System, Las Vegas, NV, USA.
Rayeheh BaharDepartment of Internal Medicine, Valley Health System, Las Vegas, NV, USA.
Azar RadfarCardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mohammadreza PakyariDepartment of Pathology, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Behnam TehraniInova Schar Heart and Vascular, Falls Church, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardio-Kidney-Metabolic (CKM) Syndrome involves metabolic, kidney, and cardiovascular dysfunction, disproportionately affecting disadvantaged groups. Its staging (0-4) highlights the importance of early intervention. While current management targets hypertension, heart failure, dyslipidemia, and diabetes, RNA-based therapies offer innovative solutions by addressing molecular mechanisms of CKM Syndrome. Emerging RNA treatments, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), show promise in slowing disease progression across CKM stages. For example, ASOs and siRNAs targeting ApoC-III and ANGPTL3 reduce triglycerides and LDL cholesterol, while siRNAs improve blood pressure control by targeting the renin-angiotensin-aldosterone system. Obesity treatments leveraging miRNAs and circRNAs tackle a key CKM risk factor. In heart failure and diabetes, RNA-based therapies improve cardiac function and glucose control, while early kidney disease trials show potential for RNAi in acute injury. Further research is essential to refine these therapies and ensure equitable access.

Indexed as

Cardio-Renal SyndromeGenetic TherapyMetabolic SyndromeOligonucleotides, AntisenseRNAi TherapeuticsRNA, Small InterferingAnimalsHumansTreatment OutcomeOligonucleotides, AntisenseRNA, Small InterferingCardio-Kidney-Metabolic (CKM) SyndromeClinical trialsRNA-based therapiesTranslational medicine

Identifiers

PMID40080261

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.